Tag: CX 2026
Venous and lymphatic session highlights continued innovation following recent PE trials
“Are we at the end of the road with this technology?” asked attendees of yesterday’s opening venous and lymphatic session at the 2026 Charing...
“Absence of endorsement is not absence of evidence”: Peripheral session raises...
Debate over sirolimus versus paclitaxel drug- coated balloons (DCBs) in the femoropopliteal segment is shifting from adoption toward optimal use, as new data and...
MOTIV primary efficacy endpoint found to be “clearly superior at 12...
Tim Wittig (Leipzig, Germany) has shared primary outcomes from MOTIV-BTK as a podium-first presentation at the 2026 Charing Cross (CX) Symposium (21–23 April, London, UK)....
